Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells

Abstract

The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.

1 . A compound having the structure shown in formula I, formula II, or formula III: 
       
         
           
           
               
               
           
         
       
     
     
         2 - 4 . (canceled) 
     
     
         5 . A composition comprising a compound having the structure shown in formula I, formula II, or formula III: 
       
         
           
           
               
               
           
         
       
       and a carrier, buffer, adjuvant, a combination of two or more of the foregoing. 
     
     
         6 . A method for treating a subject having a disorder or condition associated with aberrant or excessive Stat3 activity or interaction in a cell, comprising administering an effective amount of a compound having the structure shown in formula I, formula II, or formula III: 
       
         
           
           
               
               
           
         
       
       to the subject. 
     
     
         7 . The method of  claim 6 , wherein the disorder is an oncological disorder. 
     
     
         8 - 10 . (canceled) 
     
     
         11 . The method of  claim 6 , wherein the method further comprises, prior to said administering, determining that the disorder or condition is associated with aberrant or excessive Stat3 activity or interaction in a cell. 
     
     
         12 . The method of  claim 11 , wherein said determining comprises measuring a level of Stat3 activity or interaction in a biological sample collected from the subject and comparing the measured level to a reference level of Stat3 activity or interaction. 
     
     
         13 . The method of  claim 6 , wherein the compound is administered to the subject in a composition comprising the compound and a carrier, buffer, adjuvant, or a combination of two or more of the foregoing. 
     
     
         14 . The method of  claim 6 , wherein the subject is a mammal. 
     
     
         15 . The method of  claim 6 , wherein the subject is a non-human mammal. 
     
     
         16 . The method of  claim 6 , wherein the subject is human. 
     
     
         17 . A method for inducing apoptosis in a cell aberrantly or constitutively expressing active Stat3, comprising contacting the cell with an effective amount of a compound having the structure shown in formula I, formula II, or formula III: 
       
         
           
           
               
               
           
         
       
     
     
         18 . The method of  claim 17 , wherein the cell is a malignant cell. 
     
     
         19 - 21 . (canceled) 
     
     
         22 . The method of  claim 17 , wherein the method further comprises, prior to said contacting, determining that the cell or a representative cell aberrantly or constitutively expresses active Stat3. 
     
     
         23 . The method of  claim 22 , wherein said determining comprises measuring a level of Stat3 activity or interaction in the cell or representative cell and comparing the measured level to a reference level of Stat3 activity or interaction. 
     
     
         24 . The method of  claim 17 , wherein said contacting comprises contacting the cell with a composition comprising the compound and a carrier, buffer, adjuvant, or a combination of two or more of the foregoing. 
     
     
         25 . The method of  claim 17 , wherein said contacting is carried out in vitro. 
     
     
         26 . The method of  claim 17 , wherein said contacting is carried out in vivo. 
     
     
         27 . The method of  claim 26 , wherein said contacting comprises administering the effective amount of the compound to a human. 
     
     
         28 . A method for screening and/or diagnosing an ontological condition or disorder using a compound having the structure shown in formula I, formula II, or formula III: 
       
         
           
           
               
               
           
         
       
       wherein the condition or disorder is associated with constitutive active Stat3 expression or active Stat3 overexpression in a cell, wherein the method comprises contacting a cell with a compound having the structure shown in formula I, formula II, or formula III: 
       
         
           
           
               
               
           
         
       
       and observing the cell for induction of apoptosis. 
     
     
         29 . A kit comprising a compound having the structure shown in formula I, formula II, or formula III: 
       
         
           
           
               
               
           
         
       
       in one or more containers.